NeoGenomics (NASDAQ:NEO) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Friday, BidAskClub reports.

Several other equities analysts have also issued reports on the stock. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. ValuEngine raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Leerink Swann set a $30.00 price target on shares of NeoGenomics and gave the stock a “buy” rating in a report on Wednesday, July 31st. William Blair reaffirmed an “outperform” rating on shares of NeoGenomics in a report on Tuesday, October 29th. Finally, Benchmark set a $27.00 price target on shares of NeoGenomics and gave the stock a “buy” rating in a report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. NeoGenomics has an average rating of “Buy” and a consensus price target of $24.86.

Shares of NASDAQ:NEO opened at $23.48 on Friday. The firm has a market cap of $2.38 billion, a PE ratio of 180.62 and a beta of 0.94. The firm’s 50 day simple moving average is $20.82 and its 200-day simple moving average is $22.59. NeoGenomics has a one year low of $11.05 and a one year high of $26.89. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.05 and a current ratio of 4.24.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, October 29th. The medical research company reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.01. The business had revenue of $104.70 million for the quarter, compared to analyst estimates of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The company’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period last year, the company posted $0.05 earnings per share. Equities research analysts predict that NeoGenomics will post 0.19 EPS for the current fiscal year.

In other news, Director Steven C. Jones sold 181,339 shares of NeoGenomics stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $24.92, for a total transaction of $4,518,967.88. Following the completion of the sale, the director now directly owns 245,234 shares in the company, valued at $6,111,231.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider George Cardoza sold 19,444 shares of NeoGenomics stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $23.15, for a total transaction of $450,128.60. Following the sale, the insider now owns 345,275 shares of the company’s stock, valued at $7,993,116.25. The disclosure for this sale can be found here. Insiders sold 382,843 shares of company stock worth $9,272,947 over the last ninety days. Corporate insiders own 8.80% of the company’s stock.

Large investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its stake in shares of NeoGenomics by 3.8% during the second quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock worth $562,000 after buying an additional 945 shares during the period. BlackRock Inc. lifted its position in NeoGenomics by 8.0% during the second quarter. BlackRock Inc. now owns 14,925,327 shares of the medical research company’s stock valued at $327,462,000 after purchasing an additional 1,100,263 shares during the period. Prudential Financial Inc. lifted its position in NeoGenomics by 8.1% during the second quarter. Prudential Financial Inc. now owns 163,570 shares of the medical research company’s stock valued at $3,589,000 after purchasing an additional 12,250 shares during the period. Envestnet Asset Management Inc. lifted its position in NeoGenomics by 33.7% during the second quarter. Envestnet Asset Management Inc. now owns 36,908 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 9,309 shares during the period. Finally, King Luther Capital Management Corp lifted its position in NeoGenomics by 11.2% during the second quarter. King Luther Capital Management Corp now owns 159,567 shares of the medical research company’s stock valued at $3,501,000 after purchasing an additional 16,117 shares during the period. Institutional investors and hedge funds own 84.48% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Read More: Dogs of the Dow

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.